# A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors

> **NCT06158516** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Changhai Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Pancreatic Neuroendocrine Tumor

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06158516
- **Lead sponsor:** Changhai Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2023-11-30
- **Primary completion:** 2026-11-29
- **Final completion:** 2026-11-29
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2023-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06158516

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06158516, "A Study of Surufatinib as Adjuvant Therapy for Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06158516. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*